NW Bio: MHRA Confirms DCVax-L MAA Still Under Review, Refutes Rejection Rumors

summarizeSummary

Northwest Biotherapeutics disclosed that the UK's MHRA confirmed its DCVax-L brain cancer treatment application is still under review and has not been rejected, refuting recent rumors. The company also alleged stock manipulation tied to the false rumors.

check_boxKey Events · Product Development and Regulatory · NWBO

• MHRA Confirms MAA Still Under Review

  The UK regulator confirmed DCVax-L's marketing authorization application for glioblastoma remains under initial review, has not been refused, withdrawn or appealed, and continues to progress toward a first decision.

• Company Refutes Rejection Rumors

  Northwest Biotherapeutics categorically denied false rumors that the MHRA had rejected the application, and alleged the rumors may be part of stock manipulation following positive data presented at the BNOS meeting.

• Regulatory Overhang Removed

  The MHRA's statement directly contradicts the negative rumors, removing a key uncertainty that had pressured the stock. The application is still active with constructive interactions ongoing.

• Going-Concern Context

  The company continues to operate under a going-concern warning with increasing cash burn; a positive regulatory decision is critical to its survival and ability to raise capital.

auto_awesomeAnalysis · NWBO · Life Sciences

The MHRA's direct confirmation that the DCVax-L marketing application remains under active review and has not been rejected directly counters false rumors that had been weighing on the stock. For a company operating under a going-concern warning and with a sub-$0.20 share price, the regulatory outcome is binary — approval would transform the company's prospects, while rejection would be devastating. This filing removes an immediate overhang and suggests the review is progressing constructively, which is a material positive signal.